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Themineralocorticoid receptor (MR) binds the steroid hormones aldosterone and cortisol and has
an important physiological role in the control of salt homeostasis. Regions of the protein impor-
tant for gene regulation have been mapped to the amino-terminal domain (NTD) and termed
activation function (AF)1a, AF1b, and middle domain (MD). In the present study, we used a
combination of biophysical andbiochemical techniques to investigate the folding and function of the
MR-NTD transactivation functions. We demonstrate that MR-AF1a and MR-MD have relatively little
stable secondary structurebut have thepropensity to form-helical conformation. Induced foldingof
theMR-MDenhanced protein-protein bindingwith a number of coregulatory proteins, including the
coactivator cAMP response element-binding protein-binding protein and the corepressors SMRT and
RIP140. By contrast, the MR-AF1b domain appeared to have a more stable conformation consisting
predominantlyof-secondary structure. Furthermore,MR-AF1b specifically interactedwith theTATA-
binding protein, via an LxxLL-like motif, in the absence of induced folding. Together, these data
suggest that theMR-NTDcontains a complex transactivation systemmadeupofdistinct structural and
functional domains. The results are discussed in the context of the induced folding paradigm for
steroid receptor NTDs. (Molecular Endocrinology 151: 1935–1948, 2010)
NURSA Molecule Pages: Nuclear Receptors:MR; Coregulators: GRIP1  AIB1  CBP  SMRT  RIP140.
The mineralocorticoid receptor (MR) is a ligand acti-vated transcription factor and member of the steroid
hormone receptor (SHR) subfamily of nuclear receptors.
With its natural ligand aldosterone, it plays a major role
in the regulation of salt homeostasis in epithelial cells of
the colon and distal nephron of the kidney. The receptor
is also expressed in nonepithelial cells, including cardiom-
yoctes, neurones, and cells of the vasculature (reviewed in
Refs. 1–6). Polymorphisms and point mutations in the
receptor are associated with various diseases, including
pseudohypoaldosteronism type 1, early on-set hyperten-
sion, and cardiac dysfunction (4, 5). SHRs have a well-
characterized structural organization consisting of a
distinct amino-terminal domain (NTD) important for
transactivation of transcription [activation function
(AF)1], followed by a DNA-binding domain (DBD),
which is important for specific DNA binding and dimer-
ization, a hinge region, and at the carboxy terminus, a
ligand-binding domain (LBD) important for hormone
binding, protein-protein interactions, and further trans-
activation activity (AF2) (7, 8). Significantly, the length of
theNTDof nuclear receptors has been correlatedwith the
relative importance of the AF1 domain for receptor-de-
pendent transactivation (9). With a total length of 602
amino acids, the MR-NTD is the longest of all members
of SHR subfamily (10, 11). Three different parts within
the NTD have been identified as being important for re-
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ceptor transactivation. The groups of Kato and co-work-
ers (12) and Lombe`s and co-workers (13) identified
two regions in the human and rat MR-NTD, termed
AF1a (amino acids 1-169) and AF1b (amino acids 451-
602) that were important for transactivation. By con-
trast, Govindan and Warriar (14) reported that the
central part of the human MR (hMR)-NTD (amino
acids 247-385) acted as a transactivation domain.
However, an inhibitory function has also been reported
for this region (13).
How exactly transcriptional regulation by the MR is
distinguished from themost closely related glucocorticoid
receptor (GR) is a topic of active research and debate, and
the differences are likely to occur at several levels (4, 11,
15, 16). Given the high degree of sequence and structural
homology the MR-DBD and LBD share with the GR, it
seems likely that a critical region to distinguish the action
of both receptors lies within the NTD, which shows only
15% homology (4, 15–20).
Little is known about the MR-NTD with respect to its
folding and function. Several coactivators, such as the p160
family protein SRC2 or RNA helicase A (RHA)/cAMP re-
sponse element-binding protein-binding protein (CBP) com-
plexes have been shown to potentiate the transactivation
activity of the AF1b and AF1a domains, respectively (12,
21), but no direct link between structure and function has
been made. Studies on AF1 transactivation domains within
the NTD of the androgen receptor (AR), GR, estrogen re-
ceptor (ER), as well as progesterone receptor (PR) have
revealed that isolated recombinant proteins are largely un-
structured in solution with the potential to form structure,
which canbe induced in thepresenceof thenatural osmolyte
trimethyl N-oxide (TMAO), the hydrophobic solvent triflu-
oroethanol (TFE), interacting proteins, or other receptor do-
mains, such as the DBD (7, 8, 22–25). An induced folding
mechanism for the AR-AF1 upon TFIIF binding (26, 27)
and for the GR-AF1 upon interaction with the TATA-bind-
ing protein (TBP) (28) and an overall increase in -helical
content for both of the otherwise unstructured transactiva-
tion domains has been observed. Further more, binding of
AR-AF1andGR-AF1domains to coregulatoryproteinswas
increased after folding of the respective domains with
TMAO as shown by glutathione S-transferase (GST) pull-
downassays (27, 29). Similarly, the unstructuredER-NTD
interactedwith TBP and conformed to themodel of induced
protein folding after binding to TBP (22) and binding of the
Jun-dimerization protein 2 to the PR-DBD resulted in fold-
ing of the PR-NTD (24).
The fact that the NTD of other members of the SHR
subfamily interact with the general transcription factors
TBP or TFIIF and undergo structural changes within this
domain led to the question of whether the proposed
model of induced protein folding is common to all mem-
bers of this group of transcription factors, including the
MR-NTD. According to this paradigm, SHR-NTDs exist
in cells in a conformational state, showing significant
natural disordered structure and adopt a more folded
conformation upon protein-protein interactions when
needed to activate transcription (reviewed in Refs. 8, 23,
25). The adopted structure thereby serves as a platform
for further protein-protein interactions, leading to a com-
plex that enables transcription initiation. In the present
study, we sought to identify novel binding partners for the
MR-NTD and determine whether this region harbors
AF1 domains that conform to the model of induced pro-
tein folding. The data presented show that TBP is a spe-
cific binding partner for the AF1b domain, but that bind-
ing is not in accordance with the above model of induced
folding as shown by circular dichroism (CD) and fluo-
rescence spectroscopy and GST pull-down assays.
These data argue for alternative binding interactions of
TBP with the relatively structuredMR-AF1b domain in
contrast to the AF1 of the AR, GR, and ER. Interest-
ingly, the MR-AF1a and MR-middle domain (MD)
transactivation domains do appear to lack stable sec-
ondary structure, in the absence of structure-stabilizing
agents, and binding of coregulatory proteins to
MR-MD was enhanced by prior folding of this domain
with the natural osmolyte TMAO. Taken together, the
data suggest that the MR-NTD contains a complex
transactivation system with structurally and function-
ally distinct domains.
Results
Expression and purification of MR-AF1a, MR-MD,
and MR-AF1b domains
The structural organization of the MR is depicted in
Fig. 1A, showing the LBD, DBD, and unique NTD com-
prising amino acids 1-602. The three regions identified as
regulating transcription are highlighted below.MR-AF1a
(amino acids 1-169) is predicted to be largely -helical
(47%) and to have regions of intrinsic disorder in the
N-terminal half, between amino acids 1 and 107 and a
peak at amino acids 121-130 (Fig. 1A). The MR-AF1b
domain (amino acids 450-602) has been mapped to the
carboxy-terminal part of the NTD and is predicted to
be predominantly ordered, with a high proportion of
-strand structure (34%), a segment of disordered struc-
ture between amino acids 570 and 602, and a short
stretch of unstructured amino acids depicted by a peak
around 500-525 (Fig. 1A). The MD (amino acids 247-
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FIG. 1. MR domain organization and purified recombinant proteins. A, Schematic drawing of the hMR showing the domain organization.
Numbers indicate amino acid positions. Below is an enlarged view of the MR-NTD, amino acids 1-602, highlighting the three domains
important for MR-dependent gene regulation: AF1a, MD, and AF1b (12–14). The location of two tryptophan (W) residues is also indicated.
Below are two structure prediction plots: a PONDR plot (56, 57), which is a prediction of natural disordered structure (positive peaks above
0.5), and below, the predictions of secondary structure using Network Protein Sequence Analysis (see http://pbil.ibcp.fr/htm/index.php) (58):
the large bars represent -helix, small bars represent -strand, and the middle line represents nonordered structure. B, Coomassie-stained
gel of purified His-tagged MR-AF1a, MR-MD, MR-AF1b polypeptides, and MR-NTD. MR-AF1b was purified from the insoluble (AF1br) or
soluble (AF1bs) bacterial fractions. An asterisk indicates the copurifying bacterial FKBP type chaperone. The amount of protein loaded was
7.0, 2.0, 4.6, 3.0, and 1.7 g for MR-AF1a, MR-MD, MR-AF1bs, MR-AF1br, and NTD, respectively. C, Coomassie-stained gel of purified
GST-tagged MR-AF1a, MR-MD, AF1b, and NTD polypeptides. The amount of protein loaded was 2.7, 6.0, 1.0, and 2.8 g for MR-AF1a,
MR-MD, MR-AF1b, and MR-NTD, respectively.
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385) is predicted to have little secondary structure (77%
random coil) and to be predominantly unstructured (Pre-
dictors of Natural Disordered Regions score 0.5 and
solid line) (Fig. 1A). Expression constructs for N-termi-
nally His- or GST-tagged MR-NTD polypeptides were
generated and recombinant proteins purified as described
inMaterials andMethods. His-taggedMR-AF1b was pu-
rified from the insoluble bacterial protein fraction and
refolded in vitro (AF1br) (Fig. 1B), because under nonde-
naturing conditions, a second protein copurified with the
MR polypeptide, which was identified by mass spectrom-
etry as an Escherichia coli FK506 binding protein (FKBP)
type chaperone (AF1bs) (Fig. 1B) (data not shown). Con-
comitant with the elimination of the chaperone, there
was a loss of stability of the MR-AF1b polypeptide,
purified from the insoluble bacterial fraction. This lack of
stability became apparent during refolding as the final
dialysis step against buffer lacking urea resulted in protein
precipitation. A detergent that has been shown to stabilize
-secondary structure at low concentrations is sodium
dodecyl sulfate (SDS) (30, 31), and
when added during the last dialysis step
at a concentration of 1.7 mM, no signs
of precipitation of the His-tagged MR-
AF1b was observed. Figure 1, B and C,
shows the purified recombinant pro-
teins, which from the stained gel and
Image J quantification were estimated
to be greater than 90% pure for His-
MR-MD, His-MR-AF1br, and GST
proteins and 55 to 60% for His-MR-
AF1bs, due to the copurification of the
bacterial FKBP.
Distinct regions of the
MR-NTD contribute to
transcriptional activation
To confirm the importance of re-
gions within the NTD for transactiva-
tion, a construct was made containing
the NTD-DBD with a FLAG tag and
transfected into COS-1 cells together
with a luciferase reporter gene driven
by two glucocorticoid response ele-
ments (GREs). Figure 2A shows the
MR-NTD-DBD polypeptide and a se-
ries of deletion mutant proteins. Dele-
tion of the MD reduced the transcrip-
tional activity of the NTD by 35%,
whereas deleting AF1a or AF1b region
resulted in a loss of greater than 97%of
the activity of the full NTD (Fig. 2B).
Importantly, the AF1b domain alone
linked to the DBD retained 26% the activity of the MR-
NTD-DBD polypeptide (Fig. 1B). The wild-type and de-
letion proteins were all expressed at similar levels, with
the exception of MR-AF1a. Thus, the loss of transacti-
vation activity with this construct, in the present study,
may be a consequence of inefficient translation or in-
creased degradation. However, overall, these data are in
good agreement with published work on the MR-AF1
transactivation function.
Conformational analysis of the MR-AF1a, MR-MD,
and MR-AF1b domains
Measuring the steady-state fluorescence emission spec-
trum for a protein is a useful method for monitoring the
local tertiary structure surrounding aromatic amino acids
and the folding/unfolding of the polypeptide in different
environments. MR-AF1a and MR-AF1b both contain a
single tryptophan residue, amino acids 19 and 560, re-
spectively, and 5 or 8 tyrosine residues, respectively. The
emission spectrum for tryptophan is sensitive to changes
FIG. 2. Reporter gene activity for MR-NTD-DBD and AF1 deletions. A, Schematic
representation of the MR-NTD-DBD-FLAG construct and the transactivation domain deletions.
B, The wild-type or mutant MR-NTD-DBD constructs were transfected along with a (GRE)2-
TATA-luciferase reporter gene into COS-1 cells and transactivation activity measured.
Transfections were done in triplicate, and the mean  SD is shown. On the right is shown a
Western blot analysis of the expressed proteins detected with an anti-FLAG antibody. An
asterisk indicates a nonspecific protein detected in some blots. The % activity relative to the
wild-type protein (100%) is also shown.
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in polarity upon exposure to solvent, whereas the emis-
sion fromtyrosine residueswill bequenchedbyany trypto-
phan residues in close proximity (32). After excitation at
278 nm, MR-AF1a and MR-AF1b showed distinct emis-
sion spectra (Fig. 3). The tryptophan in MR-AF1a is es-
sentially solvent exposed with a max of 351 nm, i.e. not
significantly changed by urea-induced unfolding (Fig. 3A
and Table 1). In the presence of the osmolyte TMAO, a
natural solute that stabilizes native structure (33), there is
a clear “blue shift” of the max to 341 nm consistent with
the tryptophan residue becoming less solvent exposed.
MR-AF1a was also sensitive to rapid limited trypsin di-
gestion in the absence of TMAO, resulting in a doublet of
fragments between 14 and 20 kDa, which lack sequences
from the N terminus (Supplemental Fig. 1A, published on
The Endocrine Society’s Journals Online web site at
http://mend.endojournals.org). By contrast, the spectrum
for MR-AF1b in buffer suggests that the tryptophan is
shielded from aqueous solvent already in buffer and there
is no further change in the presence of TMAO (Fig. 3B
and Table 1). However, after urea-induced unfolding,
there was a distinct “red shift” of the max to 347 nm,
indicating that the tryptophan residue is becoming more
solvent exposed. Taken together, these results are consis-
tent with the MR-AF1b domain being stably folded,
whereas the MR-AF1a can undergo in-
duced folding in the presence of TMAO.
Given that the MR-AF1b polypep-
tide purified from inclusion bodies re-
quires low concentrations of SDS for its
stability, we addressed the question of
the conformation of this domain from
the soluble fraction under the same
buffer conditions. The max values for
tryptophan emission are summarized
in Table 1. The results were essentially
the same as for the refolded polypeptide,
with the tryptophan residue buried in
buffer, but becoming more solvent ex-
posed after urea-induced unfolding. To
investigate the conformation of MR-
AF1br in SDS in more detail, the
polypeptide was challenged with the
protease trypsin and the products of a
partial proteolytic digest analyzed over time. Although
there are 10 predicted trypsin cleavage sites within the
MR-AF1b, this domain was significantly resistant to pro-
teolytic digestion with a dominant series of fragments,
between 14 and 20 kDa, generated after 20 min, which
were identified as retaining amino terminal regions of
AF1bbyWesternblot analysis (Supplemental Fig. 1C). Even
after a 60-min incubation, there was significant levels of
full-length MR-AF1b remaining (Supplemental Fig. 1C,
filled arrowheads). This would be consistent with the struc-
ture predictions shown in Fig. 1B. Resistance to proteolytic
cleavage was not due to the inhibition of trypsin activity by
SDS, because the rates of cleavage of the artificial trypsin
substrate N--benzoyl-L-arginine ethyl ester were identical
in the presence or absence of SDS (Supplemental Fig. 1D).
In the absence of tryptophan residues, the conforma-
tion of the MR-MD polypeptide was investigated by lim-
ited proteolysis. Supplemental Fig. 1B shows that the
MR-MD polypeptide is digested in a time-dependent
manner, and this digestion is prevented in the presence of
TMAO.This is consistentwith induced folding of theMD
and adoption of a more protease-resistant conformation.
Previously, we and others have shown that TMAO does
not inhibit protease activity (34). Collectively, the data
FIG. 3. Steady-state fluorescence emission spectra for MR-AF1a and MR-AF1b. A and B, The
steady-state fluorescence emission spectra for His-tagged MR-AF1a and MR-AF1br,
respectively, in either phosphate buffer (black line), 6 M urea (gray line), or 3 M TMAO (broken
line) after excitation at 278 nm. The data are a representative experiment, and the results of
at least three independent experiments showing the mean value  SD are summarized in
Table 1. W and Y represent the emission wavelength for tryptophan and tyrosine,
respectively, for the proteins in buffer.
TABLE 1. Summary of steady-state fluorescence spectroscopy data
Mean max SD (nm)
Protein Buffer TMAO Urea  blue shift  red shift
AF1a 351  2 341  1 353  2 10 nm 2 nm
AF1br 336  3 338  3 347  3 — 9 nm
AF1bs 339  1 337  3 345  2 2 nm 7 nm
NTD 347  2 340  3 351  2 7 nm 4 nm
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suggest that the MR-AF1b is a stably folded polypeptide
in the presence of low concentrations of SDS, whereas
MR-AF1a and MR-MD are less stably folded in the ab-
sence of the osmolyte TMAO.
MR-AF1a and MR-MD polypeptides have the
propensity to form -helical conformation,
whereas MR-AF1b adopts a predominantly
-secondary structure
Far-UV CD analysis can be used to determine second-
ary structure elements of proteins by observing spectra
resulting from conformational states of peptide bonds
within proteins. We investigated the secondary structure
content of the three MR-NTD domains associated with
transactivation. Figure 4A shows the far-UV spectrum for
MR-AF1a in buffer and with increasing amounts of the
hydrophobic solvent TFE, which has been widely used as
an experimental tool to stabilize secondary structure. The
spectrum in buffer shows a strong minimum at around
197 nm, which is indicative of nonordered structure (Fig.
4A). In contrast, in the presence of increasing amounts of
TFE, there is increasing negative ellipticity at 209 and at
222 nm, which is associated with an
increase in -helical content at the
expense of both -structure and nonor-
dered structure (Fig. 4A and Table 2).
The far-UV spectra for MR-MD
showed a similar trend with a more he-
lical conformation adopted in the pres-
ence of TFE (Fig. 4B and Table 2).
TMAOwas not used in these studies, be-
cause it shows strong absorption at low
wavelengths that interferes with the re-
cording and analysis of the CD spectrum.
In 1981, Wu et al. (30) carried out
extensive CD studies on the effect of
SDS on protein structure. They con-
cluded that proteins with -structure-
forming potential can adopt this
structure in the presence of low con-
centrations of SDS (2 mM), but at
higher concentrations (25 mM), a par-
tial -sheet to helix transition can be
observed. We investigated whether the
AF1b adopts primarily -structure at
the low concentrations of SDS used
(1.7 mM/0.05%) and whether the sheet
to helix conformational changes could
be observed at higher concentrations
(up to 34 mM/1.0%) of detergent. So-
lutions of approximately 0.1 mg/ml of
highly purified AF1b were used to
record far-UV CD spectra at increasing
concentrations of SDS (Fig. 4C).With a positive ellipticity
below 200 nm and negative ellipticity between 200 and
240 nm, the spectrum of this protein is in accordancewith
FIG. 4. Secondary structure analysis of the MR-NTD transactivation functions. A and B, Far-
UV CD spectra for the MR-AF1a and MR-MD domains, at concentrations of 0.5–0.8 mg/ml,
recorded in buffer (black line) or 25 or 50% TFE (gray lines). Estimates of secondary structure
are summarized in Table 2. C, Far-UV CD spectra for the MR-AF1br, at concentrations in the
range from 0.07 to 0.2 mg/ml, were recorded in increasing concentrations of SDS. Spectra
are characteristic for a mixed / protein, with primarily -secondary structure as summarized
in Table 2. D, As for C, except 50% TFE was included in buffer (gray line).
TABLE 2. Summary of CD data for MR-NTD
transactivation system
Secondary structure
-
Helix
-
Strand
-
Turn RC Total
AF1a buffer 11 29 25 36 101
AF1a 50% TFE 63 5 10 22 100
MD buffer 13 22 24 40 99
MD 50% TFE 66 13 7 15 101
AF1b (0.05% SDS)
buffer
19 32 31 19 101
AF1b 50% TFE 13 31 23 33 100
AF1b 0.1% SDS 18 25 26 31 100
AF1b 0.5% SDS 16 27 24 33 100
AF1b 1.0% SDS 19 26 25 30 100
NTD buffer 20 21 24 35 100
NTD 50% TFE 79 2 3 15 99
Secondary structure determinations (in %) as estimated by the CDSSTR
procedure Sreerama and Woody (55). RC, Random coil.
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a spectrum resulting from a mixed / protein. The spec-
trum for the MR-AF1b domain revealed significant
-strand and turn elements comprising a total of 63% all
together in 1.7 mM SDS with only 19% -helical content
(Fig. 4C and Table 2). An overall decrease in -structure
with increasing amounts of SDS (up to 34 mM) could be
observed with concomitant increase in random coil, but
not -helix, which indicates that no induced -helical
structure is formed at higher concentrations of SDS (Fig.
4C and Table 2). Interestingly, in the presence of 50%
TFE, there was again a general increase in random coil
(Fig. 4D and Table 2), which is in contrast to the effects of
this hydrophobic solvent on the MR-AF1a and MR-MD
domains and the published studies for the AR-AF1 (26)
andGR-AF1 (35), where a significant increase in-helical
structure was observed. Although TFE has generally been
shown to induce -helix, it has also been shown to stabi-
lize -strands, and hence its action seem to depend on the
nature of the protein involved and its structure-forming po-
tential (31). Overall, the results are in accordance with the
structure predictions that the MR-AF1b
adopts-secondary structure and has lit-
tle propensity, unlike MR-AF1a and
MR-MD, to form significant amounts of
-helix.
Conformational analysis of the
full-length MR-NTD
Fluorescence and far-UV spectros-
copy analysis of the full-length MR-
NTD revealed some composite struc-
tural properties seen with the isolated
domains, but generally, the fluorescence
emission for the solvent exposed trypto-
phanwas dominant, and the polypeptide
showed a propensity to form helical sec-
ondary structure in a hydrophobic envi-
ronment (Tables 1and2andSupplemen-
tal Fig. 2, A and B). Strikingly, when the
NTD is digested with trypsin in the ab-
sence of TMAO, two prominent frag-
ments are observed, which are not recog-
nized by the antihistidine antibody
(Supplemental Fig. 2C). From the lack of
N-terminal sequences and the size of
these fragments, it is tempting to specu-
late that they represent the protease resis-
tant AF1b domain.
Multiple protein-protein
interactions with distinct regions
of the MR-NTD
Relatively few direct protein-bind-
ing partners for the MR-NTD have been identified or
characterized to date. Using an in vitro protein-protein
interaction assay, we screened panels of known general
transcription factors, coactivators, and corepressor pro-
teins for binding to MR-NTD or the isolated transactiva-
tion domains. Figure 5 shows representative results for
GST pull-down assays. Figure 5A shows the selective
binding of members of the p160 coactivator family, ste-
roid receptor coactivator (SRC)2 and SCR3, and the CBP
to theMR-MD and theMR-NTD, but only after induced
folding or stabilization of conformation by TMAO ().
Importantly, TMAO did not significantly increase bind-
ing of any of these factors to the MR-AF1a or MR-AF1b
domains or GST alone, indicating the interactions were
specific for the foldedMD. Similarly, binding of corepres-
sor proteins, SMRT and RIP140, was specific for the
MR-MDandMR-NTD after TMAO treatment (Fig. 5A).
Again there was no significant binding to either MR-
AF1a or MR-AF1b coactivator proteins, irrespective of
FIG. 5. In vitro protein-protein interactions. A, GST pull-down assays were performed with 0.7
M bait protein (GST, GST-MR-NTD, GST-MR-AF1a, GST-MR-MD, or GST-MR-AF1b) and in vitro
synthesized and radiolabeled coactivators (SRC2, SRC3, and CBP) and corepressors (SMRT and
Rip140). Experiments were done in the absence () or presence () of 3 M TMAO. The results are
representative of at least two independent experiments; 10% of the input labeled protein is
indicated. B, A representative experiment showing binding of the general transcription factor TBP
to increasing concentrations of GST alone or GST-MR polypeptides. Preferential binding to AF1b
and NTD was observed in the absence of TMAO. Quantitation of the gels shown was as follows:
AF1b: 4, 28, and 29 arbitrary units; NTD: 10.6, 16.8, and 20.8 arbitrary units; and AF1a: 1, 5.3,
and 6.9 arbitrary units, respectively. C, The wild-type (MR-NTD-DBD) or mutant (MR-NTD-MD-
DBD) constructs were transfected along with a (GRE)2-TATA-luciferase reporter gene into COS-1
cells, with or without the coregulatory proteins CBP, SRC2, or SMRT and transactivation activity
measured. Transfections were done in duplicate or triplicate, and the mean fold activation SD is
shown for one or two experiments.
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the presence or absence of TMAO (Fig. 5). By contrast,
the TBPwas found to preferentially interact with theMR-
AF1b domain, and full-length NTD, in the absence of
TMAO (Fig. 5B). No selective interac-
tions were indentified for the MR-AF1a
domain for any of the proteins tested, al-
though somemodest binding of TBPwas
seen in some experiments (Fig. 5).
In cotransfection experiments, full
length, SRC2 and CBP enhanced trans-
activation by MR-NTD-DBD by 2- and
4-fold, respectively (Fig. 5C, left panel).
In contrast, cotransfection of SMRT re-
sulted in a 50% decrease in transactiva-
tion activity of the MR-NTD (Fig. 5C,
left panel). Deletion of the MR-MD ab-
lated the coactivation by CBP and the
corepression activity of SMRT (Fig. 5C,
right panel). Collectively, the data from
protein-protein interaction assays and
cell reporter gene studies reveal that the
MR-NTD binds multiple protein targets
that may enhance or repress transactiva-
tion activity.
The interaction of CBP and TBP
with the MR-MD and MR-AF1b do-
mains, respectively, were characterized
further usingGST pull-down titrations.
Figure 6, A and B, shows the binding of
radiolabeled CBP binding to the MR-
MD. In the absence of TMAO, no specific binding was
observed to the MR-MD, or GST, as shown above (Fig.
5). However, in the presence of 3 M
TMAO, there was a concentration-de-
pendent increase in binding, which was
saturable for the CBP interaction with
MR-MD (Fig. 6, A and B). From the
curves generated and the correspond-
ing Eadie-Hofstee plot, a dissociation
constant of 0.7 M was calculated for
this interaction, as described in theMa-
terials andMethods (Fig. 6C). A similar
analysis of the interaction of TBP with
increasing amounts of GST alone or
GST-MR-AF1b, but in the absence of
TMAO, also resulted in saturable bind-
ing, and from the corresponding Eadie-
Hofstee plot, a dissociation constant of
1.4 M was calculated for this interac-
tion (Fig. 7, A–C).
Binding of TBP to MR-AF1b is
mediated by residues within a
LxxLL-like motif
Given that the structural properties
of theMR-AF1b mediating the interac-
FIG. 6. Binding of CBP to the MR-MD in the presence of TMAO. A, The binding of CBP was
measured in the presence of increasing concentrations of GST alone (not shown) or GST-MR-
MD in the absence (not shown) or presence of TMAO (). Bound CBP was analyzed after
SDS-PAGE and exposure of the dried gel to a phosphoimaging plate and visualized by AIDA
software as depicted (Bound CBP). B, Bound CBP (A) was quantified using AIDA software and
plotted as fraction of CBP bound vs. concentration of GST (squares) or GST-MR-MD
(triangles) (M)  TMAO (filled or open symbols). The result represents the pooled data from
two independent experiments. C, A Eadie-Hofstee plot of the binding data in the presence of
TMAO shown in B, from which the dissociation constant, Kd, was calculated.
FIG. 7. Binding of TBP to the MR-AF1b domain. A, The binding of TBP was measured in the
presence of increasing concentrations of GST alone or GST-MR-AF1b. Bound TBP was analyzed
after SDS-PAGE and exposure of the dried gel to a phosphoimaging plate and visualized by AIDA
software as depicted. B, Bound TBP (A) was quantified using AIDA software and plotted as
fraction of TBP bound vs. concentration of GST (x) or GST-MR-AF1b (filled squares/diamonds).
Two independent titrations are plotted for the binding toMR-AF1b, and the results are representative
of at least three independent experiments. C, A linear Eadie-Hofstee plot of the binding data in
the presence of TMAO shown in B, from which the dissociation constant, Kd, was calculated.
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tionwith TBP appear distinct from those described for the
GR-AF1 (28, 29) and the binding of CBP toMR-MD, we
investigated the binding interface inmore detail. Compar-
ison of the amino acid sequence of the MR-AF1b domain
from different species revealed clusters of highly con-
served amino acids (Fig. 8A) (data not shown). A series of
triple or single mutations were introduced into AF1b at
these conserved residues, in the context of MR-NTD-
DBD and the isolated domain (MR-AF1b) (Fig. 8A and
Supplemental Fig. 3). Mutating two serine residues and a
leucine at positions 468, 469, and 470 (M5) (Fig. 8A) was
predicted to disrupt local -structure and increase -he-
lix. Mutating these residues or the leucine alone at 469
(M8) (Fig. 8A) impaired transactivation activity in the
context of MR-NTD-DBD (Fig. 8B). Mutations intro-
duced into other conserved residues at positions 494, 495,
and 496 (M6), 516, 517, and 518 (M7), or single point
mutations at I672A (M9) and A512G (M10) also reduced
transactivation activity by 30–35% (Supplemental Fig.
3). This reduction in activity is unlikely to be due to
changes in receptor levels, because all the mutant
polypeptides were expressed to a similar level as the wild-
type protein (Fig. 8B and Supplemental Fig. 3). Interest-
ingly, the M5 and M8 mutations also disrupted the bind-
ing of TBP, resulting in reduced binding and a 2- to 3-fold
reduction in binding affinity (Fig. 8C and Table 3). The
effect of the triple (M5) or single (M8) mutations on TBP
binding and activity is not due to gross changes in con-
formation. The max for tryptophan fluorescence emis-
sion was 339 and 338 nm for M5 and M8, respectively,
and was not significantly different from the wild-type
protein (336 nm) (Fig. 9A), and both the wild-type and
M5 mutant polypeptides showed similar protease sensi-
tivity (Fig. 9B). Taken together, the results of mutational
FIG. 8. Mutation of polar and hydrophobic amino acids impair transactivation and TBP binding. A, Primary amino acid sequence alignment of the
MR-AF1b domain from human, rat, and mouse; up to 10 additional species were included in the full analysis, including the receptor sequence
from Xenopus and several fish species. Black represents residues conserved in all species studied. The boxes represent three triple mutations M5
(S468A, L469A, and S470A), M6 (K497A, Q495A, and E496A), and M7 (V516A, N517A, and S518A), which were introduced into MR-NTD or MR-
AF1b. A single point mutation, M8 (L489A), is also indicated. Secondary structure predictions are shown below the sequence alignment: arrows
represent -strand, and the lines represent random coil. B, The mutant or wild-type MR-NTD-DBD-FLAG constructs were transfected into COS-1
cells together with the (GRE)2-TATA-luciferase reporter gene and transactivation activity measured. Transfections were done in triplicate, and the
mean  SD is shown. Above is shown a Western blot analysis of the expressed proteins detected with a anti-FLAG antibody. An asterisk indicates a
nonspecific protein detected in blots for the MR-NTD-FLAG constructs. The % activity relative to the wild-type protein (100%) is also shown. C,
The binding of TBP was measured in the presence of increasing concentrations of GST alone or GST-MR-AF1b wild-type (filled diamonds) or the
M5 (filled squares) and M8 (x) mutant polypeptides. Bound TBP was quantified using AIDA software and plotted as fraction of TBP bound vs.
concentration of GST-MR-AF1b polypeptide (M). An estimate of the dissociation constant, Kd, for the different MR-AF1b-TBP binding interactions
was calculated as described in the legends to Figs. 6 and 7 and the results summarized in Table 3. The data for M5 are from a single experiment,
whereas the data for M8 are representative of two independent experiments.
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studies suggest that residues next to or within a highly
conserved LxxIL motif in MR-AF1b are important for
both transactivation and TBP binding. LxxLL motifs in
coregulatory proteins have previously been shown to be
important for ligand-dependent binding to a hydrophobic
pocket on the surface of the LBD (36).
Discussion
The MR-NTD contains a modular transactivation sys-
tem, involving discrete regions of the protein. In the
present study, we have characterized the structural and
functional properties of these regions. The full-length
MR-NTD and the isolated MR-AF1a and MR-MD
polypeptides appear to have little stable secondary struc-
ture in aqueous buffer, but have the propensity to form
-helical conformation in a hydrophobic environment.
Further, a solvent-exposed single tryptophan within
AF1a underwent a significant blue shift in the presence of
the natural osmolyte TMAO, and this domain adopted a
more protease resistant conformation. This is indicative
of the local environment becoming less solvent exposed
and is consistent with induced folding of this domain.
Similarly, the MR-MD, which lacks tryptophan residues,
adopted a more protease-resistant conformation in the
presence of TMAO consistent with induced or stabilized
folding. By contrast, MR-AF1b appears to adopt a stable,
primarily, -structure in aqueous buffer and showed little
propensity to form -helix in the presence of high con-
centrations of either SDS or TFE. Figure 10 summarizes
the structural properties of theMR-NTD and the isolated
domains.
Using in vitro protein-protein interaction assays with
GST-tagged proteins, a number of direct binding partners
were identified for the MR-MD. These binding interac-
tions included both coactivators and corepressors, but
significantly binding was only observed after folding of
this domain or the full-length NTD with TMAO. Criti-
cally, TMAO treatment did not significantly increase the
binding of any of the target proteins tested to either
MR-AF1a or MR-AF1b domains. The MR-MD has
been proposed to act either positively or negatively in
gene regulation (13, 14), which would be consistent with
interactions with both coactivators and corepressors. The
exact function of this domain may depend on cellular or
gene context, and the observed structural plasticity would
be advantageous for forming multiple specific protein-
protein interactions with modest affinities.
A relatively modest number of coregulatory proteins
has been identified that modulates MR-dependent trans-
activation (see Refs. 5 and 8 and references therein).
Members of the p160 coactivator family have been shown
to potentiate MR-NTD-dependent transactivation, but
no direct interactions were reported (12, 37). Protein-
protein interactions with the MR-NTD have been inves-
tigated by two-hybrid analysis, GST pull-downs, and
chromatin immunoprecipitation assays, and direct bind-
ing has been observed for RHA (21), the corepressor
DAXX (38), as well as the SUMO-1 E2 conjugating en-
zyme ubc9 (39) and the E3 ligases, pro-
tein inhibitor of activated signal trans-
ducer and activator of transcript (PIAS)
1 and PIAS x (13) and the elongation
factor eleven-nineteen lysine-rich leu-
kemia (ELL) protein (40). ELL en-
hanced MR transactivation activity
and the interaction is particularly inter-
esting, because the binding was
mapped in part to the AF1b region
(40). RHA was shown to bind directly
to the MR-AF1a domain and to form a
trimeric complex with CBP (21). In the
present study, we show that CBP, and
p160 proteins, can bind directly to the
MR-MD and result in enhanced trans-
activation by the MR-NTD. However,
none of the coregulatory proteins
FIG. 9. Mutating residues in a LxxIL motif does not alter gross structure. A, The steady-state
fluorescence spectra for wild-type (WT) and M5 AF1br polypeptides are shown. The max for
tryptophan emission was similar for all three proteins (WT, 336 nm; M5, 339 nm; and M8,
338 nm). B, Limited proteolysis of wild-type and M5 MR-AF1b. The polypeptides were
digested with trypsin for the time points indicated and the fragments resolved by SDS-PAGE
and detected by Coomassie staining. The pattern of fragments generated (open arrow heads)
was essentially identical for both polypeptides.
TABLE 3. TBP binding to MR-AF1b mutations
Protein Mutation Activitya Kd
b
MR-AF1b WT 100% 1.4 M
M5 S468A, L469A, S470A 64% 4.6 M
M8 L469A 64% 2.9 M
WT, Wild type; Kd, dissociation constant.
a Reporter gene assay using MR-NTD-DBD-FLAG.
b Binding affinity determined from a representative GST pull-down
assays (Figs. 7 and 8) or a single titration experiment in the case of M5.
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tested showed preferential binding to MR-AF1a domain
in either the presence or absence of the structure stabiliz-
ing osmolyte TMAO, although this domain showed sim-
ilar structural properties of induced folding as MR-MD.
TBP was observed to specifically interact with MR-
AF1b with an apparent binding affinity of 1.4 M. A
similar binding affinity, in the range 1-10 M, has been
reported for the binding of TBP to the ER-NTD (22), but
5- to 9-fold higher affinities were observed for TBP bind-
ing to the GR-AF1 (0.19 and 0.25 M) (41) and the Gal4
transactivation domain (0.16 M) (42). A model for cou-
pled protein-protein binding and induced folding based
on binding kinetics has been proposed by Wright and
co-workers (43, 44). They have argued for a two-stage
binding reaction, with an initial fast step mediated by
electrostatic interactions and a subsequent slower step
involving hydrophobic interactions and induced folding.
It is interesting, therefore, that the binding of TBP to
MR-AF1b, although not requiring induced folding, was
modulated by mutating both polar and nonpolar amino
acids in a region containing a LxxLL-like motif. This sug-
gests that both long-range electrostatic interactions and
hydrophobic surfaces may also play a role in stable struc-
ture-mediated protein-protein binding.
The binding of TBP to the GR-AF1 (28), ER-NTD
(22), and c-myc-transactivation domain (45) increased
the level of secondary structure in these proteins. A selec-
tive interactionwith TBPwas identified for theMR-AF1b
domain, which was independent of prior induced folding
or stabilization of structure. For the MR-AF1b, no dra-
matic change in secondary structure was observed upon
complex formation (Supplemental Fig. 4) or on the sol-
vent exposure of the single tryptophan residue, indicative
of local tertiary structure, after treatment with TMAO. In
contrast to AR, GR, and ERNTD/AF1 domains, theMR-
AF1b showed little propensity to form helical structure.
Collectively, our data suggest that the structural basis of
MR-AF1b binding to TBP is by a distinct mechanism that
does not require induced folding of this region of the
MR-NTD. Earlier studies with the yeast activators Gal4
andGcn4 transactivation domains revealed that they con-
tained significant -structure and similar to MR-AF1b
showed little propensity to form -helix (46). Taken as
whole, the available evidence suggests that, although in-
duced folding and adoption of a more helical structure is
a common mechanism for transactivation domains, it is
not necessarily a prerequisite for transactivation activity,
and other more stable structures can also serve this func-
tion.Our data for theMR-NTD transactivation functions
illustrate this multiplicity of structure-function relation-
ships within a single transcription factor. The data, to-
gether with the previously published studies, also argue
for the ability of different secondary structure elements to
bind coregulatory proteins and regulate transcription.
A number of investigations of the structure of nuclear
receptorNTDs has identified considerable levels of intrin-
sic disordered structure, which has led to a general model
for the conformational plasticity for this domain and the
adoption of predominantly -helical structure upon spe-
cific protein-protein interactions (22, 24, 26–28) or phos-
phorylation (47, 48). The MR-AF1a and MR-MD sub-
domains clearly fit with this general model, but in
contrast, the MR-AF1b appears to exhibit a high degree
of structural stability. The concept of intrinsic disorder
and its role in protein function has gained wide-spread
acceptance in recent years, and the existence of an ensem-
ble of conformations for these regions has been proposed
(8, 23, 49–51). A number of advantages has been high-
lighted for coupling protein folding with protein-protein
interactions, including binding specificity without the re-
quirement for high affinity, large interface surface, and
the ability to interact with multiple binding partners.
More recently, Hilser andThompson (52) have developed
an additional functional model for intrinsic disordered
structure involving allosteric coupling and domain-do-
main interactions. Their model proposes that varying de-
grees of protein stability and interdomain communication
underpin the ensemble of structural conformations, and
this primes the system for functional interactions (52).
The data presented here for the MR-NTD would be con-
sistent with such a model. In the absence of protein-pro-
tein, or DNA interactions or posttranslational modifica-
tions, the NTD or regions within this domain exhibit
structural plasticity, which undergo induced folding upon
FIG. 10. Summary of the structural and functional properties of the
modular MR-NTD transactivation function. Schematic drawing of the
MR-NTD showing the three transactivation domains and the position
of two tryptophan residues (W). Selected secondary structure content
is summarized, and induced folding in the presence of TMAO or TFE is
indicated by an arrowhead and the solid cylinders and arrows. The
binding of coregulatory proteins to MR-MD and MR-AF1b is also shown.
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specific interactions. This then creates one or more sur-
faces that promote further interactions. The evidence
from the present study suggests that some regions within
the NTD, e.g. the MR-AF1b domain, are more stably
folded and can interact with protein targets in the absence
of induced folding. It is tempting to speculate that the
binding of TBP to the AF1b domain may induce structure
in other parts of the MR-NTD, analogous to the binding
of Jun-dimerization protein 2 to the PR-DBD (24). Fur-
ther experiments will be required to test this hypothesis.
In conclusion, we have identified structural differences
in MR-AF1b domain compared with the GR-AF1 that
underpin specific interactions with a common binding
partner (TBP), which may also contribute to the selectiv-
ity of theMR response in target cells. It will be interesting
to investigate the structural consequences of TBP binding
for other regions of the MR-NTD and to consider the
structural basis of different protein-protein interactions
and the impact on receptor action.
Materials and Methods
Plasmid construction
The cDNA for hMR-NTD-DBD was amplified by PCR using
the plasmid pRShMR (a gift from Ronald Evans; Salk Institute,
San Diego, CA) as a template and the Expand system (Roche,
Welwyn Garden City, Hertfordshire, UK). Primers: forward, 5
GCGCGCAGTTCTACCCCGGCGGAGGCAGGA 3 and re-
verse, 5 GCGCGCAGATCTCCATCActtgtcatcgtcgtccttgtagtc-
CTTTCCCAACTTCTTTGACTTTCG 3; small letters represent
the engineered FLAG tag, and the stop codon is underlined. The
PCR product was digested with BglII and cloned into pcDNA3.1
() Hygro vector (Invitrogen, Paisley, Scotland, UK) digested with
BamHI. Positive clones were identified by restriction enzyme di-
gestion and confirmed by DNA sequencing.
The cDNAs for the isolated hMR-NTD, MR-AF1a, MR-
MD, and MR-AF1b domains were amplified by PCR using the
plasmid pRShMRas a template and the Expand system (Roche).
The sequence of primer pairs for amplification is available on
request. The PCR fragments were digestedwithBglII and cloned
into either pET19bm (53) or pGEX2TK (Amersham Bio-
sciences, Chalfont St Giles, Bucks, UK) at theBamHI cutting site
for expression of recombinantHis- or GST-taggedMRpolypep-
tides, respectively. Positive cloneswere confirmed by sequencing
and transformed into BL21 (DE3) pLys cells (Novagen, Darm-
stadt, Germany) for expression of recombinant proteins.
Mutagenesis
Deletion and point mutations of amino acids within theMR-
NTD or AF1b region were introduced using double-stranded
oligonucleotides and the Quickchange method (Statagen,
Workingham, Berkshire, UK). Mutations were screened by re-
striction endonuclease digestions and the mutation confirmed
by DNA sequencing.
Reporter gene assays
COS-1 cells were transfected with wild-type or mutant MR-
NTD-DBD expression constructs, together with the (GRE)2-
TATA-luciferase reporter gene plasmid, using lipofectamine
2000. After 24 h, cells were harvested, lysed (Promega lysis
buffer; Promega, Madison, WI) and luciferase activity mea-
sured. Themeasured relative light units were normalized to total
protein recovered (determined by the method of Bradford) and
protein expression checked by Western blot analysis using an
anti-FLAG antibody (Sigma-Aldrich, Poole, Dorset, UK). In co-
transfection experiments, expression plasmids for full-length
CBP (0.05 g pRSV-CBP-HA), SRC2 (0.5 g pSG5-TIF2),
SMRT (0.15 g pCMX-mSMRT-FL), and/or empty vector
control was included.
Purification of recombinant proteins
Expression of His- or GST-tagged MR polypeptides was in-
duced at OD600 0.4–0.6 by addition of 1 mM isopropyl -D-
thiogalactoside for 3 h and incubation at 37 C or with 0.1 mM
isopropyl -D-thiogalactoside and incubation for 1.5 h at 28 C,
respectively. Bacterial cultures [BLR (DE3) cells] were grown in
2xTY media (16 g/liter Bactotryptone, 10 g/liter yeast extract,
and 5 g/liter NaCl) containing 0.4 g/liter ampicillin and 0.03
g/liter chloramphenicol. Cell pellets were lysed by freeze thaw-
ing and incubation with 0.5 mg/ml lysozyme at 4 C, and recom-
binant proteins were purified from the soluble (GST-tagged pro-
teins and His-tagged MR-AF1a, MR-MD, and MR-NTD) or
insoluble fraction (His-tagged MR-AF1b). Soluble proteins
were purified on glutathione-sepharose 4B resin (Amersham Bio-
sciences) or Ni-NTA resin (QIAGEN, Crawley, West Sussex, UK)
according to standard procedures, checked by SDS-PAGE for pu-
rity, and dialyzed against 25mMHEPES (pH7.5), 100mM sodium
acetate, 5% (vol/vol) glycerol, and 1 mM dithiothreitol (protein
dialysis buffer). Insoluble proteins were purified under denaturing
conditions in urea (54), checked by SDS-PAGE for purity, and
dialyzed against protein dialysis buffer containing 1.7 mM SDS
during the last steps of dialysis to prevent precipitation.
CD spectroscopy
Purified His-tagged MR-polypeptides were dialyzed against
4 mM NaH2PO4, 6 mM Na2HPO4, 100 mM NaSO4, 10% (vol/
vol) glycerol, and 1 mM dithiothreitol containing 1.7 mM SDS
for the AF1b polypeptide. Far-UV CD spectra were measured at
20 C on a Jasco J-810 spectropolarimeter calibrated with (1S)-
()-10-camphorsulfonic acid. A cell of 0.02-cm path length was
used to obtain far-UV spectra (190–260 nm). The far-UV CD
spectra for MR-AF1b were also measured in the presence of
increasing concentrations of SDS (3.5, 17.3, and 34.7 mM cor-
responding to 0.1, 0.5, and 1.0%, respectively) and 50% (vol/
vol) TFE. The proportions of each secondary structure type
were estimated from the CD data using the CDSSTR procedure
(55). In each case, the quality of the fitting procedurewas judged
by the very low value (0.03) of the normalized root mean
square deviation and the very good superposition of the exper-
imental and reconstructed spectra. Protein concentrations were
between 0.07 and 0.2 mg/ml.
Fluorescence spectroscopy
His-tagged MR-AF1a and MR-AF1b polypeptides were an-
alyzed using a Shimadzu 1501 spectrofluorimeter with excita-
tion and emission band widths of 10 nm using a 1-cm path
length cuvette. The emission spectra of 0.025 mg/ml protein in
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dialysis buffer containing either 6 M urea or 3 M TMAO were
measured after excitation at 278 nm.
Partial proteolysis assay
Purified His-tagged MR polypeptides were diluted to a final
concentration of 1 M and digested in proteolysis buffer [25mM
HEPES (pH 7.5), 10% (vol/vol) glycerol, 0.2 mM EDTA, 5 mM
MgCl2, 20mMCaCl2, and 60mMKCl] at 30 C for varying times
with 0.006 g/liter trypsin. Reactions were stopped by the addi-
tion of 12.5 l 4	 SDS sample buffer and heating at 75 C for 5
min. Samples were resolved by SDS-PAGE and followed by
either silver staining or Western blot analysis with a mouse
monoclonal antihexahistidine antibody (Sigma, St. Louis, MO)
and detection with enhanced chemiluminescence.
Activity assay of trypsin
The artificial trypsin substrate N--benzoyl-L-arginine ethyl
ester (0.46 mM) was incubated with 0.012 g/liter trypsin in 63
mM sodium phosphate, 0.06 mMHCl in the presence or absence
of SDS. The reactions were monitored at 253 nm, and absor-
bance readings were taken every 2 min for 45 min.
GST pull-down titration assays
Various concentrations of GST-tagged MR-NTD, MR-
AF1a, MR-MD, and MR-AF1b proteins or GST alone were
incubated with 25 l glutathione-sepharose 4B resin (Amer-
sham Biosciences) in 100 l PBS for 30 min at 4 C, and centri-
fuged pellets containing bound proteins were resuspended in
GST pull-down buffer [20 mM HEPES-KOH (pH7.9), 10%
(vol/vol) glycerol, 100 mM NaCl, 5 mM MgCl2, 0.2 mM EDTA,
0.1% (vol/vol) Tween 20, 0.02 g/liter BSA, 1 mM dithiothreitol,
and 0.2 mM phenylmethylsulfonylfluoride] in the presence or
absence of TMAO and incubated for 30 min at 4 C to allow
protein folding. Subsequently, 3–5 l of 35S labeled prey pro-
teins (Promega TNT Coupled Reticulocyte Lysate System),
including CBP (pRSV-CBP-HA), SRC2 (pSG5-TIF2), SRC3
(pCMX-ACTR), RIP140 (pCMV-RIP140), SMRT (pCMX-
mSMRT-FL), or human TBP, were added, incubated for 2 h at
4C,washed three times in 180l GST pull-down buffer, and the
centrifuged pellets resuspended in 20 l of 2	 SDS sample
buffer. Samples were analyzed by SDS-PAGE followed by phos-
phoimaging analysis. In the titration pull-down assay, the frac-
tion of CBP or TBP boundwasmeasured and plotted against the
concentration of GST or GST-bait proteins. The dissociation
constants for the binding of CBP and TBP were calculated from
the slope of linear plots of Bound Partner Protein v’s Bound
Partner/[MR domain] (Eadie-Hofstee plot).
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